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Effects of  -Trinositol on Peripheral Circulation in Diabetic Patients with 
Critical Limb Ischaemia. A Pilot Study Using Laser Doppler Fluxmetry, 
Transcutaneous Oxygen Tension Measurements and Dynamic 
Capillaroscopy 
L. Nilsson *~, J. Apelqvist 2 and L. Edvinsson 2 
Departments of ~Surgery and 2Internal Medicine, University Hospital, S-221 85 Lund, Sweden 
Objectives: To evaluate whether a-trinositol may have an effect on the microcircutation i  patients with diabetes meltitus 
and critical ischaemia. 
Material and methods: Ten patients with previously known diabetes mellitus and with critical limb ischaemia were 
given a-trinositol during a 24 h infusion, resulting in a total dose of 2400 rag. Microcirculation was evaluated by means 
of laser doppler fluxmetry (LDF), transcutaneous oxygen tension (tcP02) and dynamic apillaroscopy (CBV). 
Results: Plasma concentration of c~-trinositol reached asteady state level after I h following the start of the administration. 
There were no detectable changes in blood pressure or heart rate. Laser Doppler flux increased from 41% to 57.5% and 
tcP02 changed from 116 to 91 s in "half time recovery" after occlusion. Capillary blood flow showed an increase in 
resting velocity from 0.1 to 0.5 mm/s at 24 h. 
Conclusions: The infusion of ~.-trinositol did not cause any changes in the haemodynamics in general, but resulted in 
changes in LDFcres t v~ue), tCOa(h~l~-ti . . . . . . . . .  y) and CBW(res t flow) during or following the infusion suggesting improved 
microcirculation. 
Key Words: Diabetes mellitus; ~-trinositoI; Laser Doppler fluxmetry; Transcutaneous oxygen tension; Dynamic 
capillaroscopy. 
Introduction 
There is limited information regarding incidence and 
prevalence of chronic critical limb ischaemia (CLI); 
however, it has been calculated to be around 500-1000 
per million individuals in the western world. 1'2 
Modulation of the sympathetic nervous system, e.g. 
ganglion destruction, alpha-adrenergic blockade or 
reserpine treatment, has previously been tried in un- 
reconstructable critical limb ischaemia with variable 
success. 1 The focus has been directed towards the 
adrenergic receptors; however, recent studies have 
shown that neuropeptide Y (NPY), a sympathetic co- 
transmitter with noradrenalin, 3 may have pronounced 
vascular effects. We have demonstrated that ~-tri- 
nositol (D-myo-inositol 1.2.6-trisphosphate) is a fairly 
potent and selective NPY antagonist 4 which can block 
NPY-induced contraction or potentiation of nor- 
adrenalin induced contractions, NPY-mediated in- 
creases in phosphatidyl inositol formation and the rise 
in intracellular Ca 2+ concentration. 5,6 
*Please address all correspondence to: L. Nilsson, Department of
Surgery, University Hospital, S-221 85 Lund, Sweden. 
The aim of the present study was thus to evaluate 
whether ~-trinositol may have a beneficial effect on 
the microcirculation i patients with diabetes mellitus 
and critical ischaemia. 
Material and Methods 
Subjects 
Ten patients (six men and four women; median age 
68 years (range 51-81)) with diabetes mellitus and 
critical limb ischaemia (defined in the European Con- 
sensus Document on Critical Limb Ischaemia, March 
1989) were recruited by the diabetes foot care team. 
All patients had a present or previous foot ulcera- 
tion and a systolic toe blood pressure between 
10-35 mmHg. Four patients had undergone toe am- 
putation, one was previously treated with PTA and 
one with rt-PA. All patients had been examined by 
femoral angiography and evaluated by a vascular 
surgeon, and were considered unsuitable for invasive 
1078-5884/98/040331+06 $12.00/0 © 1998 W.B. Saunders Company Ltd. 
332 L. Nilsson et al. 
Table 1. Time intervals for measurements of blood flow, laser Doppler fluxmetry, oxygen tension and c~-trinositol. First measurement 
beginning 4 (-4) h before start of infusion. 
Time (h) - 4 - 1 0 1 2 4 6 10 12 23 24 
:z-Trinositol infusion continuously 
CBF x x x x x 
LB x x x x x 
tcPO2 x x x x x 
Blood pressure continuously 
cz-Trinositol p asma conc. x x x x x x x x x 
intervention, and only those patients in whom it was 
possible to achieve measurements of microcirculation 
were included in the study. Patients with severe con- 
gestive heart failure (NYHA IIMV) or ischaemic heart 
disease with myocardial infarction within 6 weeks 
prior to investigation, severe liver or kidney in- 
sufficiency or foot gangrene were excluded. The study 
was approved by the Ethics Committee of the Uni- 
versity of Lund. 
Stu& design 
Microcirculation was evaluated by means of laser Dop- 
pler f luxmetry (LDF), transcutaneous oxygen tension 
(tcPO2) and dynamic capillaroscopy (CBV) at the fol- 
lowing time points in relation to start of the bolus 
infusion: -4 ,  -1 ,  4, 12 and 24 h. 
~-Trinositol (a gift from Perstorp Pharma, Lund, 
Sweden) was given first as an intravenous bolus 
(240 mg ~-trinositol during 10 rain) and this was fol- 
lowed by a 24 h infusion of ~-trinositol in saline at a 
rate of 90 mg/h .  The total dose of ~-trinositol given was 
2400 mg during 24 h. ~-Trinositol (molecular weight of 
529.9g/mol), packed as a freeze-dried powder in 
sealed vials, was reconstituted in saline immediately 
before use to give a stock solution of 100 mg/ml  and 
then further diluted with sterile isotonic saline to 
give a solution with 24mg/ml  of ~-trinositol. The 
remainder of the stock solution was further diluted to 
9.0 mg/ml  and used for the continuous i.v. infusion. 
Samples to determine the plasma concentration of
cz-trinositol were taken I h before infusion and then at 
1, 2, 4, 6,10,12, 23 and 24 h after the start of the infusion. 
Routine blood samples were taken at admission and 
after drug infusion and included: Na +, K +, creatinine, 
Hb, HbAlc, triglycerides, cholesterol, haematocrit, 
platelet count, leukocytes, aspartate (ASAT) and al- 
anine (ALAT) aminotransferases. These were analysed 
at the Department of Clinical Chemistry, University 
Hospital, Lund. 
~-Trinositol in plasma was assayed with a com- 
petitive radioimmunoassay (RIA) using an antiserum 
raised against 1D-myo-inositol-l,2,6-trisphosphate 
hemisuccinate BSA conjugate. 7 Tritium labelled 1D- 
myo-inositol-l,2,6-trisphosphate w s used as a tracer. 
Antibody-bound ~-trinositol was separated from free 
fraction by a double antibody polyethylene glycol 
(PEG) precipitation technique. The radioactivity in 
the precipitate was measured with a /3-scintillation 
counter. This methodology has a detection limit of 
5 nmol/1. The interaction with e.g. 1,4,5-inositol-1,4, 
5-trisphosphate is non-significant. Venous blood for 
analysis of ~-trinositol was collected from the contra- 
lateral arm in relation to the one used for the infusion. 
Recordings 
ECG was recorded at admission. Blood pressure was 
monitored every 20 rain during daytime (06:00-23:00) 
and every hour at night-time with a blood pressure 
scan (SpaceLabs Inc.). LDF, tcPO2, and CBV were 
measured twice before infusion at - 4 h and - 1 h and 
three times during infusion of cz-trinositol at +4, + 12 
and +24h (see Table 1). 
Laser doppler f luxmetry was measured with a laser 
Doppler fluxmeter (Periflux Pf2 standard probe, Peri- 
med LinkOping, Sweden). The output signal from 
the fluxmeter is linearly related to moving cells and 
particles in a small tissue volume and will be frequently 
shifted according to the Doppler effect. The technique 
has been described in detail elsewhere. 89Flux curves 
were registered with a pen recorder using a paper 
speed of i mm/s.  Gain selector was set at 30 with a 
range of 4 kHz and the time constant at 3.0. The flux 
is defined in arbitrary units. Full scale deflection is 
one hundred in arbitrary units. Laser doppler flux 
was measured under steady state conditions with 
the patient resting in a supine position. The values 
obtained were resting values and peak values after 
release of occlusion. For this purpose the limb was 
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occluded uring 10 min with a torniquet. The 10 min 
of occlusion was necessary to reach a steady state of 
the oxygen tension value recorded simultaneously. 
Transcutaneous oxygen tension was measured with 
a cutaneous pOa monitor 820 (Kontron Ltd, Zurich, 
Switzerland) with a Clark pO 2 electrode and a range 
of 0-106 kPa and displayed on a high contrast LCD 
monitor. The instrument was calibrated before every 
recording and in accordance with the prevailing air 
pressure and the sensor temperature selector set to 
45 °C. 
The equipment for dynamic capillaroscopy meas- 
urements consists of a microscope (Leitz Laborflux 12 
ME D) with a magnification of 500 x connected to a 
video-camera (Ikegami CTC 2110 with a silicon diode 
tube RCA 4532) and a videotape recorder. The micro- 
scopy table is constructed in such a way that it can be 
tilted to a suitable angle. The microscope is mounted 
on a holder that allows movements in both directions 
to scan the toe nailfold capillaries. A metal bracket 
was used to stabilise the toe under observations in the 
microscope. The laser Doppler and the oxygen tension 
probes were placed on the base of the observed toe. 
The setup is described in detail by Fagrel et al. ~° The 
skin temperature of the area of observation and the 
microscope image produced on the monitor were re- 
corded on videotape for subsequent analysis on a 
computerized system (CapiFlow®) that allows 
measurement of capillary blood flow velocity (CBV) 
and post-occlusive reactive hyperaemia (PRH). The 
method uses a dual window technique. The intensity 
variations in the windows positioned across a vessel 
are measured and the velocity is then calculated by 
correlation technique. The CapiFlow program cal- 
culates the peak CBV and time to peak CBV during 
the PRH period. Capillary flowmetry was possible to 
study in the same visual field from one examination 
to the other because of careful positioning of the 
microscope and a mark on the nailfold. Furthermore, 
there was a typical architecture of the capillary bed 
that made it possible to recognise the individual 
capillary for repeated measurements. The room 
temperature was kept constant and the toe skin tem- 
perature was measured before and after the events 
but no change was seen during the study. 
Statistics 
Values were expressed as median with 95% confidence 
intervals. For comparison between groups WinSTAT 
version 3.0 Wilcoxon test for non-parametric dis- 
tribution and repeated measures analysis of variance 
was used. ~ 
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Results 
Patients 
The characteristics of the patients included are given 
in Table 2. No adverse vents were encountered during 
the study and the patients tolerated the infusion with- 
out symptoms. There were no changes in blood chem- 
istry following ~-trinositol infusion (data not shown). 
a- Trinositol evels 
Plasma concentration of ~-trinositol reached a steady 
state level already i h after the start of the ad- 
ministration. The median concentration during the 
remaining of the infusion period was 24.5__+ 1.7 retool/1 
(data not shown). 
Haemodynamics 
There was no detectable change in systolic or diastolic 
blood pressure during the infusion of ~-trinositol (data 
not shown). The overall median blood pressure was 
140/82 mmHg at dayt ime (max-min = 189-130/85-70) 
and 146 / 75 at night time (max-min = 177-128 / 93-66). 
Average heart rate was 70 bpm during day time and 
68 bpm at night time (max-min = 106-56 resp. 95-51). 
There was no change in heart rate during the ~- 
trinositol infusion (data not shown). 
m 
Before infusion During 24 h infusion 
CBV rest value Laser doppler flux changed from 41%-57.5% (p = 0.01) 
at resting activity but no change was seen at the peak 
values (Fig. 1). 
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Fig. 1. Laser Doppler fluxmetry, basal activity: values represent 
median with 95% confidence intervals. 
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Fig. 2. Tissue oxygen pressure. Time to regain 50% of the total 
oxygen pressure reduction that occurred during occlusion 
(tcO2(half -t i  . . . . . . . . . . .  y)) ,  Values represent median with 95% confidence 
intervals. 
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Fig. 3. Capillary blood flow velocity (CBV), rest value. Values 
represent median with 95% confidence intervals. 
Tissue oxygen pressure showed a change from 
116-91 s (p = 0.03) in half time to recover after occlusion 
but no change regarding basal activity (Fig. 2). 
Using the Capif low program it was possible to 
measure CBV-restflow before infusion in eight subjects 
and after infusion in seven subjects. A change in 
restflow from 0.1-0.5 mm/s  (p = 0.05) was seen at 24 h 
in those cases (Fig. 3). 
Discussion 
The present pilot study of diabetic patients with critical 
l imb ischaemia showed an improvement  in micro- 
circulation after infusion of a-trinositol; however, there 
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was no control group. A critically low systolic toe 
blood pressure has been shown to indicate a high 
probability for the development of foot gangrene and 
the need for amputation. 12 In diabetic patients a systolic 
toe blood pressure below 35 mmHg has been con- 
sidered as an adequate definition of critical isch- 
aemia. 13'14 There are few reported studies in diabetic 
patients with foot lesions and critical ischaemia 
showing the possibility that local circulation can be 
improved by non-invasive pharmacological inter- 
ventions. ~5 Recently, trials comparing intra-arterial or 
intravenous infusion of prostanoids have been con- 
ducted for short durations (3-4 days of infusion) 16-19 
and long-term (7-28 days). 2°-22 There have been 
favourable results in two of the long-term trials a°'22 
but not in the others. 
The choice of a-trinositol as the drug in the in- 
vestigation was based on the assumption that sym- 
pathectomy has, in some patients, been seen to have 
a positive effect on CLI, 23 albeit of relatively short 
duration. Since ¢~-trinositol has been found to be an 
NPY antagonist, he blockade of NPY might provide 
a new type of remedy to this group of subjects. The 
present study has shown that the current methodology 
provides stable levels of LDF, TcO2 and CBV at rest 
and following a 60 s-10 rain occlusion with subsequent 
reflow. The administration f a-trinositol resulted al- 
ready within i h in stable plasma levels. The drug did 
not cause any adverse ffects or any changes in heart 
rate or blood pressure throughout the study. Thus, a- 
trinositol infusion results in stable haemodynamics n 
the general circulation. The infusion of ~-trinositol 
resulted in changes in LDFi~e~tvalue), tcO2(half.ei . . . . . . . . . . . .  y) 
and CBV/~e~t ow/during or following the infusion. This 
suggests improved microcirculation. 
There is increasing evidence that a-trinositol, al- 
though it has similarities with inositol-l,4,5-tri- 
phosphate (IP3) , has unusual pharmacological 
attributes, a-Trinositol appears to act selectively as a 
blocker of NPY effects both in vivo and in vitro. 4"5"24 It 
has been found to block the potentiating effect of 
noradrenalin and the direct contractile ffects of NPY, 
to attenuate the rise in IP3 and in intracellular Ca 2+ 
elicited by iv NPY. 5'24'25 Furthermore, ~-trinositol may 
normalise platelet aggregation to ADP and thrombin 
in rats with streptozotocin (STZ) -induced diabetes 
mellitus, 26 to prevent he reduction in sciatic motor 
nerve conduction velocity and to suppress in part the 
increased resistance to hypoxic conduction blocky It 
is not known if these actions of a-trinositol in STZ- 
treated rats are due to inhibition of an effect mediated 
by endogenous NPY, although 27it has been suggested 
that the beneficial effects of a-trinositol n sciatic nerve 
function may have been due to a vascular action. The 
in vivo haemodynamic effects of ~-trinositol are not 
known in detail because previous tudies have mainly 
focused on short-term effects on the circulation. 7 Re- 
cently, Gardiner et aI. 28 examined the effects of long 
term infusion of ~-trinositol on regional haemo- 
dynamics in the rat. They observed that ~-trinositol 
caused a significant rise in blood flow and in vascular 
conductance in some vascular egions, such as renal, 
mesenteric and hindquarter vascular beds. The in- 
crease in hindquarter blood flow and in vascular con- 
ductance were maximal within 3 h of the onset of ~- 
trinositol infusion, whereas the effects in renal and 
mesenteric vascular beds developed much more 
slowly with maximum at about 24 h. While it is feasible 
that the mechanisms behind the ~-trinositol-induced 
vasodilatation are different in the various vascular 
beds, the possibility that the slower onset of the renal 
and mesenteric vasodilator effect of ~-trinositol is due 
to more effective autoregulation in the gastrointestinal 
vascular beds than in the hindquarters. The fact that 
there was no significant hypotension or tachycardia 
at this stage suggests that the increase in regional 
blood flow must have been met by an increase in 
cardiac output, or by substantial steal from other 
vascular territories. It is interesting to note that in the 
experiments with c*-trinositol infusion during 24 h in 
men, the significant increments were only seen to- 
wards the end of the infusion period. This agrees well 
with the study by Gardiner et al. 28 who only observed 
late effects. In concert with their data, we saw no 
change in heart rate or in blood pressure during short- 
term infusion in patients; however, a slight reduction 
in blood pressure and an increment in heart rate were 
seen. 7The present results cannot be compared with 
previous reports of the cardiovascular effects of ~- 
trinositol since those studies involved relatively short 
duration administration f the drug or challenge with 
NPY. 7 It remains to be determined what accounts 
for the haemodynamic profile of ~-trinositol during 
chronic infusion. 
In summary, the effects described in the present pilot 
study require valuation i a long-term perspective for 
CLI. However, it may be that a-trinositol has beneficial 
effects on CLI without affecting general haemo- 
dynamics. 
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